10-17-Daily AI News Daily
Today’s Summary
Monte Rosa's NEK7 degrader hit a median 85% hsCRP drop across 108 subjects in Phase 1, and Tenvie's CNS-penetrating NLRP3 inhibitor dosed its first patient the same day — anti-inflammaging now has two early-stage clinical programs running in parallel.
Big pharma is writing billion-dollar acquisition checks instead of building in-house, Prenuvo just opened 200K MRI scans to researchers, and senescent cell-derived extracellular vesicles are spreading aging signals on their own — together these signals point to the field shifting from mechanism discovery toward data infrastructure and clinical pipeline buildout.
Readers should first verify the peer-review status of Monte Rosa's GFORCE-1 data and the post-hoc analysis limitations of the Longeveron preprint before drawing conclusions about the near-term clinical value of the NLRP3 pathway.🔥 Today’s Top 9 Highlights
1. AI Uncovers SRSF1 Gene That Extends Lifespan in Aging Mice by 14%
According to Google News aggregated reporting , SRSF1 — an RNA splicing factor flagged by AI screening — is linked to a “rejuvenation” effect that extended lifespan in aging mice by 14%. This is a secondary source; the original paper, journal, sample size, and intervention details are all unverified. The only confirmed takeaway: the work sits at the intersection of AI-assisted target discovery and aging biology, and animal results don’t translate directly to humans.
2. Blocking the STING Pathway Preserves Bone Density in Aging Mice 🦴
Lifespan.io reports that a Chinese research team published in Advanced Science showing that macrophage-specific silencing of Sting in 12–18-month-old mice significantly preserved bone density, bone structure, and reduced bone marrow adipocyte numbers. The study mapped out a signaling chain: bone marrow adipocyte-secreted DPP4 activates STING via TLR4 in concert with mitochondrial DNA leakage, which then drives CD38-mediated extracellular NAD⁺ degradation and impairs mitochondrial function in neighboring bone progenitor cells. The drug combo (STING inhibitor H-151 + NMN) performed comparably to the established anti-osteoporosis drug alendronate. Caveats: mouse study, small sample, and the combined treatment makes it hard to isolate individual contributions — no human data yet.
3. Monte Rosa’s NEK7 Degrader Shows Drops Across Multiple Inflammation Markers in Phase 1 📉
Longevity.Technology reports that Monte Rosa Therapeutics completed the GFORCE-1 study (Phase 1/pilot, 4-week dosing) in 108 obese subjects at elevated cardiovascular risk. The molecular glue degrader MRT-8102 drove a median ~80–90% drop in NEK7 protein levels; downstream markers followed — hsCRP down 85%, IL-6 down 54%; plaque-associated signals calprotectin, S100A12, and SAA fell by 56%, 46%, and 51% respectively. The adverse event rate (33%) was close to placebo (30%), with no increased infection signal. Data came from a company announcement — no peer-reviewed publication yet. A 4-week improvement in blood biomarkers does not equal fewer cardiac events; Phase 2b GFORCE-2 is expected to kick off in H1 2027.
4. Prenuvo Opens 200K Full-Body MRI Scans to 50+ Research Institutions 🧠
Longevity.Technology reports that Prenuvo announced the Prenuvo Research Network on September 29, adding over 200,000 full-body MRI scans to a research biobank. A preliminary analysis of 78,000+ voluntary screening participants found 7% had clinically significant brain abnormalities (including aneurysms, infarcts, and meningiomas). Partner institutions include UCSF, City of Hope, Moffitt Cancer Center, and 50+ others. Key caveat: participants are all self-selected, paying customers — not representative of the general population. The causal link between imaging findings and improved survival outcomes remains unproven, and each sub-study calls for follow-up prospective validation.
5. Longeveron’s MSC Therapy Preprint Hints at Slowing Neuroinflammation in Alzheimer’s 🧬
Longevity.Technology reports that Longeveron posted a post-hoc exploratory analysis on medRxiv (based on the published CLEAR MIND Phase 2a trial, n=49): laromestrocel (Lomecel-B) hit p < 0.05 on free water MRI in the left hippocampus, with reduced neuroinflammation tracking alongside improved MoCA cognitive scores and lower plasma neurogranin. Caveats are stacking up here — preprint, not yet peer-reviewed, post-hoc analysis, tiny sample, correlation ≠ causation, the product isn’t FDA-approved, and the company is simultaneously on an investor roadshow.
6. Kailera’s Obesity Drug Phase 3 Enrollment Is Full — Results Due 2028 ⏳
Longevity.Technology reports that Kailera Therapeutics has completed enrollment for all three KaiNETIC Phase 3 trials (~4,900 participants total), with a top dose of 10 mg over 76 weeks per trial. KaiNETIC-3 includes a direct open-label comparison against semaglutide 2.4 mg. Top-line data is expected mid-2028. There’s no efficacy or safety data to analyze right now, and whether this GLP-1/GIP dual agonist translates into longer healthspan is a question a 76-week trial simply can’t answer.
7. Tenvie’s CNS-Penetrating NLRP3 Inhibitor Enters Phase 1 Human Trials 🧪
Longevity.Technology reports that Tenvie Therapeutics dosed its first participant with TNV313 on October 13, kicking off a randomized dose-escalation Phase 1 safety and pharmacokinetics study in healthy volunteers. TNV313 is positioned as a fully CNS-penetrating oral NLRP3 inhibitor targeting neuro, cardiometabolic, and ophthalmic diseases. Preliminary safety and PK data are expected in H1 2027. This is Phase 1 — it’s assessing safety and tissue distribution only, not inferring efficacy for any neurodegenerative disease.
8. Big Pharma Is Buying, Not Building — Longevity Is Now M&A Territory 💰
Longevity.Technology’s analysis notes that large pharma runs 62% of all registered industry trials in core aging pathways, yet virtually every concrete 2025–2026 deal has been an external acquisition: Lilly–Insilico at $2.75B, Roche/Chugai–Gero at up to $1B; an industry patent cliff of ~$100B through 2028 helped drive 2025 life sciences M&A to $240B (up 81% YoY). These figures are from base-case report assumptions, not realized values. AbbVie’s 11-year Calico collaboration ended in November 2025 with no approved products — a reminder that in-house aging research has its own sky-high failure rate.
9. Senescent Cell-Derived Extracellular Vesicles Spread Aging Signals Independently of Classic SASP 🔬
Lifespan.io reports that a cell study published in Aging compared the secretomes of H-RASG12V-induced senescent cells versus p16-overexpressing cells: p16 cells barely secreted soluble SASP factors like IL-1β and IL-6, but pumped out more small extracellular vesicles (sEVs). Those sEVs drove recipient cells to express p16 and SA-β-gal (senescence markers) and triggered DNA damage (γH2AX) — without triggering classic inflammatory cytokines. The effect was validated using sEVs from elderly donors applied to infant fibroblasts. Caveats: in vitro only, the specific cargo inside the sEVs hasn’t been identified, and whether targeting sEVs is therapeutically feasible hasn’t been explored.
⚡ Product & Feature Updates
Digbi Health Folds HRT Into Its Multi-Omics Precision Health Platform
Longevity.Technology reports that Digbi Health has integrated hormone replacement therapy (HRT) into its existing precision biology platform — members can now get GLP-1 and HRT prescriptions from the same clinical team, with personalized protocols built on genomic, gut microbiome, continuous glucose, and blood biomarker data. The rollout expands coverage to all 50 US states via OpenLoop Health and MD Integrations, reaching 300+ employers. The company cites published research showing $3,012 in savings per member per year — but that data predates the HRT launch, and the HRT module itself has no independent efficacy or cost data yet. The platform sells to employers and health plans, not directly to individual consumers.
🧪 Frontier Research
Bisphenol Mixtures Reprogram Epigenetic State in Human Breast Organoids
According to GEN’s reporting , researchers from Tufts University and Boston University published in PNAS using 3D breast organoids from 13 healthy young women to test individual and combined exposures to BPA, BPS, and BPF. Single exposures showed limited effects, but low-dose mixture exposure — at concentrations matching real human blood and urine detection levels — disrupted normal breast development in most donors’ organoids, inducing extracellular matrix remodeling, epithelial plasticity, and DNA methylation reprogramming. The molecular alteration patterns closely overlapped with data from invasive lobular carcinoma patients. An AI-assisted high-content screening platform was used to quantify developmental disruption. Caveats: in vitro organoid model, small donor sample size, cannot prove the chemicals cause cancer, and whether these molecular changes persist in human tissue and lead to disease requires prospective study.
◎ Industry Shifts & Personal Impact
Cell & Gene Therapy Scale-Up Faces Systemic Bottlenecks
According to a BioLife Solutions e-book report published by GEN , attendees at the 2026 Cell Summit — including researchers, clinicians, manufacturers, and CDMOs — reached consensus that the next core challenge for CAR-T and other cell and gene therapies is a scalable “operating system”: manufacturing, reimbursement, logistics, and data governance need to work in sync, because any broken link means patients wait. This industry assessment doesn’t include specific efficacy data — it’s useful for readers tracking regenerative medicine accessibility and production infrastructure progress. Commercial sustainability remains to be proven empirically.
⌘ Top Open Source Projects
kkontras/NeuroAtlas: Cross-Task Benchmark Suite for EEG Foundation Models
NeuroAtlas is an EEG foundation model evaluation framework covering four task categories: sleep staging, brain age estimation, epilepsy detection, and brain-computer interfaces (BCI). The paper was accepted at NeurIPS 2026. It’s a solid pick for developers and researchers working on neural signal processing, brain age biomarkers, and cross-task transfer learning. The repo dropped on 2026-10-16 with 18 stars currently; check the repo README for license details, dataset terms, and environment requirements — none of this has been independently verified.
JackieHanLab/PAOPAC: Proteome-Driven Organ Proxy Aging Clock
PAOPAC (Proteome-Aware Organ Proxy Aging Clock) uses proteomic data to build biological age proxy clocks for individual organs — a multi-omics aging measurement tool. It’s aimed at researchers working on proteomics and aging biology or organ-specific biological age estimation. The repo was published on 2026-09-21 with 2 stars; check the repo documentation for the specific datasets used, license, and algorithm details — all pending independent verification.
❓ Related Questions